公告显示，神州细胞于2025年12月5日收到上海证券交易所出具的《关于北京神州细胞生物技术集 团股份公司向特定对象发行股票的交易所审核意见》，公司向特定对象发行股票申请符合发行条件、上 市条件和信息披露要求。上海证券交易所将在收到公司申请文件后提交中国证监会注册。 神州细胞表示，公司本次向特定对象发行A股股票事项尚需获得中国证监会作出同意注册的决定后 方可实施，最终能否获得中国证监会同意注册的决定及其时间尚存在不确定性。公司将根据该事项的进 展情况及时履行信息披露义务。 神州细胞于10月15日发布的《2025年度向特定对象发行A股股票募集说明书(修订稿)》显示，本次 发行募集资金总额不超过90,000.00万元（含本数），扣除发行费用后拟全部用于补充流动资金。 本次发行的发行对象为公司控股股东拉萨爱力克投资咨询有限公司（简称"拉萨爱力克"），拉萨爱 力克以现金方式认购本次发行的股票，拟认购金额不超过人民币90,000.00万元（含本数）。 本次发行的定价基准日为公司第三届董事会第二次会议决议公告日，发行价格为36.00元/股，不低 于定价基准日前20个交易日公司股票交易均价的80%。 中国经济网北京12月8日 ...

证券代码：688520 证券简称：神州细胞 公告编号：2025-042 北京神州细胞生物技术集团股份公司 关于2025年度向特定对象发行A股股票申请 收到上海证券交易所审核意见通知的公告 登录新浪财经APP 搜索【信披】查看更多考评等级 "北京神州细胞生物技术集团股份公司向特定对象发行股票申请符合发行条件、上市条件和信息披露要 求。本所将在收到你公司申请文件后提交中国证监会注册。" 公司本次向特定对象发行A股股票事项尚需获得中国证券监督管理委员会（以下简称"中国证监会"）作 出同意注册的决定后方可实施，最终能否获得中国证监会同意注册的决定及其时间尚存在不确定性。公 司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 北京神州细胞生物技术集团股份公司董事会 2025年12月6日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"）于2025年12月5日收到上海证券交易所出具的 《关于北京神州细胞生物技术集团股份公司向特定对象发行股票的交易所审 ...

证券代码：688520 证券简称：神州细胞 公告编号：2025-042 公司本次向特定对象发行 A 股股票事项尚需获得中国证券监督管理委员会 （以下简称"中国证监会"）作出同意注册的决定后方可实施，最终能否获得中 国证监会同意注册的决定及其时间尚存在不确定性。公司将根据该事项的进展情 况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 北京神州细胞生物技术集团股份公司董事会 2025 年 12 月 6 日 北京神州细胞生物技术集团股份公司 关于 2025 年度向特定对象发行 A 股股票申请收到 上海证券交易所审核意见通知的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"）于 2025 年 12 月 5 日收到上海证券交易所出具的《关于北京神州细胞生物技术集团股份公司向特 定对象发行股票的交易所审核意见》，具体意见如下： "北京神州细胞生物技术集团股份公司向特定对象发行股票申请符合发行 条件、上市条件和信息披露要求。本所将在收到你公司申请文件后提交中国证监 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Insights - The PD-1/VEGF dual antibody track is progressing rapidly in clinical trials, with four drugs entering the registration clinical stage globally as of December 2025 [6][15] - In the fourth week of November, the pharmaceutical and biotechnology sector rose by 2.67%, outperforming the CSI 300 index by 1.03 percentage points, ranking 17th among 31 sub-industries [8][18] - The report recommends focusing on innovative drugs and their industrial chain (CXO + research services), with short-term attention on investment opportunities related to influenza [9] Summary by Sections Section 1: PD-1/VEGF Dual Antibody Clinical Progress - As of December 2025, four PD-1/VEGF dual antibodies have entered the registration clinical stage globally [15] - Shenzhou Cell is set to conduct a head-to-head registration Phase III clinical trial for SCTB14 against Pembrolizumab in first-line treatment for locally advanced or metastatic NSCLC [15] - Pfizer has registered over fifteen clinical trials for PD-1/VEGF dual antibodies globally from September to November 2025, including six global trials for SSGJ-707 [15] Section 2: Market Performance - The pharmaceutical and biotechnology sector increased by 2.67% in the fourth week of November, outperforming the CSI 300 index [18] - The raw material drug sector saw the highest increase of 4.9%, while the blood products sector experienced the largest decline of 0.45% [22] Section 3: Investment Recommendations - The report suggests a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drugs and related sectors [9][27]

Core Viewpoint - The stock of Shenzhou Cell has shown a significant increase of 41.24% year-to-date, despite recent fluctuations in trading performance and a notable decline in revenue and net profit for the first nine months of 2025 [2][3]. Group 1: Stock Performance - As of November 13, Shenzhou Cell's stock price rose by 2.01% to 51.17 CNY per share, with a trading volume of 61.31 million CNY and a turnover rate of 0.27%, resulting in a total market capitalization of 22.79 billion CNY [1]. - Year-to-date, Shenzhou Cell's stock has increased by 41.24%, with a 1.27% rise over the last five trading days, a 6.26% decline over the last 20 days, and a 21.35% drop over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Shenzhou Cell reported a revenue of 1.31 billion CNY, representing a year-on-year decrease of 32.27%. The net profit attributable to shareholders was -251 million CNY, a significant decline of 267.17% compared to the previous year [2]. - The company has appeared on the stock market's "Dragon and Tiger List" three times this year, with the most recent appearance on July 4, where it recorded a net purchase of 87.53 million CNY [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Shenzhou Cell increased by 40.96% to 13,700, with an average of 32,390 circulating shares per shareholder, a decrease of 29.06% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the sixth largest with 4.62 million shares, while Southern CSI 500 ETF holds 2.61 million shares, a decrease of 93,400 shares from the previous period [3].

Core Viewpoint - The biopharmaceutical sector experienced a slight increase of 0.44% on November 12, with significant gains from specific stocks, while the overall market indices showed a decline [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4000.14, down 0.07% - The Shenzhen Component Index closed at 13240.62, down 0.36% [1] Group 2: Top Gainers in Biopharmaceutical Sector - BGI Innovation (300318) led the gains with a closing price of 7.20, up 20.00% with a trading volume of 651,300 shares and a transaction value of 458 million yuan - Sanyuan Gene (920344) followed with a closing price of 33.15, up 12.45% and a trading volume of 85,300 shares [1] - Other notable gainers include: - Sangfor Biopharma (688336) at 68.50, up 6.60% - Sai Sheng Pharmaceutical (300485) at 12.88, up 4.63% [1] Group 3: Market Capital Flow - The biopharmaceutical sector saw a net inflow of 325 million yuan from institutional investors, while retail investors experienced a net outflow of 317 million yuan [2] - The top stocks by net inflow from institutional investors included: - Sangfor Biopharma (688336) with a net inflow of 136 million yuan - He Yuan Biopharma (688765) with a net inflow of 108 million yuan [3]

Core Viewpoint - Shenzhou Cell's stock has shown significant volatility, with a year-to-date increase of 40.52%, but recent declines in the short term raise concerns about its performance [1][2]. Company Overview - Shenzhou Cell, established on April 23, 2007, and listed on June 22, 2020, is based in Beijing and focuses on the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune disorders [1]. - The company's main business revenue is derived entirely from product sales [1]. Financial Performance - For the period from January to September 2025, Shenzhou Cell reported a revenue of 1.312 billion yuan, a year-on-year decrease of 32.27%, and a net profit attributable to shareholders of -251 million yuan, reflecting a significant decline of 267.17% [2]. - As of September 30, 2025, the number of shareholders increased by 40.96% to 13,700, while the average circulating shares per person decreased by 29.06% to 32,390 shares [2]. Stock Market Activity - As of November 10, Shenzhou Cell's stock price was 50.91 yuan per share, with a market capitalization of 22.672 billion yuan [1]. - The stock has experienced a net outflow of 4.3243 million yuan in principal funds, with significant buying and selling activity from large orders [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 4, where it saw a net purchase of 87.5322 million yuan [1]. Shareholder Composition - As of September 30, 2025, the sixth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 4.6168 million shares as a new shareholder [2]. - The seventh-largest shareholder is Southern CSI 500 ETF, which reduced its holdings by 93,400 shares [2]. - The tenth-largest shareholder is Innovation Drug, also a new entrant with 1.7893 million shares [2].

Core Points - The company will hold a Q3 2025 earnings presentation on November 17, 2025, from 10:00 to 11:00 AM [2][4] - The presentation will be conducted in an online interactive format, allowing investors to engage and ask questions [3][5] - Investors can submit questions from November 10 to November 14, 2025, through the Shanghai Stock Exchange's roadshow center or via the company's email [2][5] Meeting Details - The meeting will take place on November 17, 2025, from 10:00 to 11:00 AM [4] - It will be held online via the Shanghai Stock Exchange's roadshow center [4][5] - Key participants include the company's Chairman and General Manager, Dr. Xie Liangzhi, and other senior executives [4] Investor Participation - Investors can join the earnings presentation online on the specified date and time [5] - Questions can be pre-submitted through the roadshow center or the company's email before the deadline [5] Contact Information - The contact department for inquiries is the Securities Department, reachable at 010-50812198 [6] - Additional inquiries can be directed to the company's email: ir@sinocelltech.com [7]

Core Viewpoint - The company, Beijing Sinocell Technology Group Co., Ltd., is set to hold a Q3 2025 earnings presentation on November 17, 2025, to discuss its operational results and financial status with investors [2][3][4]. Group 1: Meeting Details - The earnings presentation will take place on November 17, 2025, from 10:00 to 11:00 AM [4]. - The format of the meeting will be an online text interaction, hosted on the Shanghai Stock Exchange's roadshow center [4][5]. - Participants will include the company's Chairman and General Manager, Dr. Xie Liangzhi, along with other key executives [4]. Group 2: Investor Participation - Investors can participate in the earnings presentation by logging into the Shanghai Stock Exchange's roadshow center on the scheduled date [5]. - A pre-question submission period is available from November 10 to November 14, 2025, allowing investors to submit questions via the roadshow center or the company's email [5]. Group 3: Contact Information - The contact department for inquiries is the Securities Department, reachable at phone number 010-50812198 and email ir@sinocelltech.com [7].